{"id":"rivaroxaban-or-marcumar","safety":{"commonSideEffects":[{"rate":"2-4%","effect":"Bleeding (major and minor)"},{"rate":"1-2%","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1%","effect":"Intracranial hemorrhage"},{"rate":"5-10%","effect":"Dyspepsia"},{"rate":"1-3%","effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban selectively inhibits Factor Xa, a serine protease essential for thrombin generation and clot formation, providing rapid anticoagulation. Marcumar works through a different mechanism by antagonizing vitamin K-dependent clotting factors (II, VII, IX, X), requiring several days to achieve full effect. These are distinct anticoagulant classes with different pharmacokinetics and monitoring requirements.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation by blocking a key enzyme in the coagulation cascade, while Marcumar (phenprocoumon) is a vitamin K antagonist that inhibits clotting factor synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:23.073Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) treatment and prevention"},{"name":"Pulmonary embolism (PE) treatment and prevention"},{"name":"Acute coronary syndrome (Rivaroxaban only)"}]},"trialDetails":[{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT03563937","phase":"","title":"Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-15","conditions":"Atrial Fibrillation","enrollment":64920},{"nctId":"NCT02066662","phase":"PHASE4","title":"Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2013-07","conditions":"Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT), Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location","enrollment":192},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT02723981","phase":"PHASE4","title":"COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials","status":"WITHDRAWN","sponsor":"IHF GmbH - Institut für Herzinfarktforschung","startDate":"2016-04","conditions":"Stable Angina, Unstable Angina, STEMI","enrollment":""},{"nctId":"NCT01674647","phase":"PHASE3","title":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Atrial Fibrillation","enrollment":1504},{"nctId":"NCT01812200","phase":"PHASE4","title":"Antithrombotic Triple Therapy in Humans","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-10","conditions":"Atrial Fibrillation, Acute Coronary Syndrome","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10064,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xarelto; Marcumar"],"phase":"marketed","status":"active","brandName":"Rivaroxaban or Marcumar","genericName":"Rivaroxaban or Marcumar","companyName":"RWTH Aachen University","companyId":"rwth-aachen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation by blocking a key enzyme in the coagulation cascade, while Marcumar (phenprocoumon) is a vitamin K antagonist that inhibits clotting factor synthesis. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}